← Dashboard
Stock
BMRN
BioMarin Pharmaceutical IncHealth CareBiotechnologyLatest close $508 of 27 marquee funds currently hold3 CUSIPs mapped
Current holders
8
27 funds tracked
Ever held
14
Current + past
New this quarter
0
Exited this quarter
0
Marquee-fund ownership over time
May 14, 2014Nov 14, 2017May 15, 2024Feb 17, 2026
Now
10
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Bridgewater Associates re-entered | Q2 2014 | 49Q | $58 | $50 | -15% |
| Viking Global Investors re-entered | Q2 2016 | 41Q | $86 | $50 | -43% |
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $89 | $50 | -44% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $90 | $50 | -45% |
| D.E. Shaw | Q3 2024(8Q snapshot) | 7Q | $90 | $50 | -45% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $90 | $50 | -45% |
| Millennium Management re-entered | Q3 2024(8Q snapshot) | 7Q | $0.00 | $50 | — |
| Point72 Asset Management re-entered | Q4 2024(8Q snapshot) | 6Q | $66 | $50 | -24% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Two Sigma Investments 2× in & out | Q1 2025 | Q2 2025 | — | +0% |
| Soros Fund Management | Q3 2024 | Q4 2024 | → $66 | -27% |
| Third Point | Q1 2024 | Q2 2024 | → $80 | -7% |
| Maverick Capital | Q3 2021 | Q1 2022 | → $90 | +20% |
| Duquesne Family Office | Q3 2020 | Q2 2021 | → $77 | -35% |
| JANA Partners | Q4 2016 | Q3 2017 | → $83 | -10% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at BIOMARIN PHARMACEUTICAL INC. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
Filings · last 30d
11
Filings · last 90d
22
Total on file
636
Recent SEC buffer
Most recent
Jun 4, 2026
30d / 90d windows measured from Jun 4, 2026 — the most recent Form 4 on file — not from today.
- Form 40001628280-26-040922Jun 4, 2026
- Form 40001628280-26-040920Jun 4, 2026
- Form 40001628280-26-040918Jun 4, 2026
- Form 40001628280-26-040916Jun 4, 2026
- Form 40001628280-26-040914Jun 4, 2026
- Form 40001628280-26-040911Jun 4, 2026
- Form 40001628280-26-040909Jun 4, 2026
- Form 40001628280-26-040907Jun 4, 2026
- Form 40001628280-26-040903Jun 4, 2026
- Form 40001628280-26-037455May 21, 2026
- Form 40001628280-26-033639May 11, 2026
- Form 40001628280-26-019862Mar 19, 2026
- Form 40001628280-26-019857Mar 19, 2026
- Form 40001628280-26-019853Mar 19, 2026
- Form 40001628280-26-019847Mar 19, 2026
Showing 15 of 636 recent Form 4 filings. Browse all on EDGAR ↗
Fundamentals
XBRL · BioMarin Pharmaceutical IncAnnual figures sourced directly from BioMarin Pharmaceutical Inc's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Revenue
$3.22B
FY2025+13% YoY
Net income
$348.9M
FY2025-18% YoY
EPS (diluted)
$1.80
FY2025-19% YoY
Free cash flow(?)
$724.96M
FY2025+49% YoY
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for BIOMARIN PHARMACEUTICAL INC — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventJun 4, 2026
- 10-QQuarterly reportMay 5, 2026
- 8-KMaterial eventMay 4, 2026
- 8-KMaterial eventApr 27, 2026
- 8-KMaterial eventApr 23, 2026
- DEF 14AProxy statementApr 21, 2026
- 8-KMaterial eventMar 16, 2026
- 10-KAnnual reportFeb 26, 2026
- 8-KMaterial eventFeb 23, 2026
- 8-KMaterial eventFeb 12, 2026
- 8-KMaterial eventJan 29, 2026
- 8-KMaterial eventJan 26, 2026
- 8-KMaterial eventJan 12, 2026
- 8-KMaterial eventDec 22, 2025
- 8-KMaterial eventDec 19, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Point72 Asset Management | Q1 2026 | open | $60 | $50 | -17% |
| Millennium Management | Q4 2025 | open | $0.00 | — | +0% |
| Two Sigma Investments | Q1 2025 | Q2 2025 | $0.00 | — | +0% |
| Point72 Asset Management | Q4 2024 | Q3 2025 | $66 | $58 | -12% |
| Citadel Advisors | Q3 2024 | open | $90 | $50 | -45% |
| Soros Fund Management | Q3 2024 | Q4 2024 | $90 | $66 | -27% |
| Two Sigma Investments | Q3 2024 | open | $90 | $50 | -45% |
| D.E. Shaw | Q3 2024 | open | $90 | $50 | -45% |
| AQR Capital Management | Q3 2024 | open | $90 | $50 | -45% |
| Millennium Management | Q3 2024 | Q4 2024 | $0.00 | — | +0% |
| Millennium Management | Q3 2024 | open | $90 | $50 | -45% |
| Renaissance Technologies | Q3 2024 | open | $89 | $50 | -44% |
| Third Point | Q1 2024 | Q2 2024 | $86 | $80 | -7% |
| Viking Global Investors | Q1 2022 | open | $90 | $54 | -40% |
| Maverick Capital | Q3 2021 | Q1 2022 | $75 | $90 | +20% |
| Bridgewater Associates | Q2 2021 | open | $77 | $54 | -30% |
| Duquesne Family Office | Q3 2020 | Q2 2021 | $118 | $77 | -35% |
| Viking Global Investors | Q2 2018 | Q3 2020 | $89 | $119 | +34% |
| Viking Global Investors | Q4 2016 | Q4 2017 | $93 | $81 | -12% |
| JANA Partners | Q4 2016 | Q3 2017 | $93 | $83 | -10% |
| Bridgewater Associates | Q4 2016 | Q1 2017 | $92 | $90 | -2% |
| Viking Global Investors | Q2 2016 | Q3 2016 | $86 | $93 | +8% |
| Bridgewater Associates | Q2 2014 | Q3 2014 | $58 | $64 | +10% |
Caveats
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.